Amgen sues Colorado over its prescription drug affordability board; Viking Therapeutics to move its oral obesity drug into Phase 2 study after early success

Taking stock of the drug industry, from the lab to the medicine chest

March 26, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Ric Francis/AP STAT+ | Amgen sues Colorado over its prescription drug affordability board The move comes one month after the state board determined that a big-selling Amgen medication called Enbrel is unaffordable. By Ed Silverman STAT+ | Viking Therapeutics to move its oral obesity drug into Phase 2 study after early success The company said it would move the oral formulation of its obesity drug into a Phase 2 trial later this year. By Andrew Joseph STAT+ | FDA is still struggling to inspect clinical research sites, watchdog finds In 2022, the FDA inspected 537 hospitals and clinics conducting studies of medicines, down from 976 sites in 2017, the GAO found. By Ed Silverman J Pat Carter/AP STAT+ | European antitrust regulators probe Zoetis over pain drug for dogs EU regulators says that Zoetis may have unlawfully prevented the entry of a novel medicine to treat chronic pain in dogs. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser